Bendamustine in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Bendamustine in multiple myeloma.

Bendamustine in multiple myeloma.

http://www.wikidata.org/entity/Q38530583

about

Novel agents in the treatment of multiple myeloma: a review about the future ALKBH7 drives a tissue and sex-specific necrotic cell death response following alkylation-induced damage.Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis

P2860

Q26745924-13FE651D-48C7-442D-9510-74BE20C4209F Q41335643-8FCC4362-CBE5-4DE2-B30C-06593A179CFE Q41970310-113D8D2C-AFB9-4F7F-8D46-D5270CAF31E9 Q58795876-7CC86F4D-A924-4220-8273-2C6D387C3A4E

P2860

Bendamustine in multiple myeloma.

http://www.wikidata.org/entity/Q38530583

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Bendamustine in multiple myeloma.

@en

type

label

Bendamustine in multiple myeloma.

@en

prefLabel

Bendamustine in multiple myeloma.

@en

P1433

Q38530583-B71AE37B-845B-4F63-B2AD-CEAB68951915

P1476

Q38530583-8C3EF851-DA24-4F0D-9B27-536F61AB501E

P2093

Q38530583-1502F02B-E0BA-4B60-AFE5-9BF75DD71A0D

Q38530583-7E0365B8-B022-4000-BC93-D63F6BAECD4E

Q38530583-829776E1-13EC-43B5-A33E-54E124191620

Q38530583-ACCCF59D-31FB-4161-AE0A-DCEFE0030A73

Q38530583-BB0833EA-971E-44C6-8C73-32E23927294A

Q38530583-DC22D7CE-5AD9-43DD-A4B0-E1AF620886AC

P2860

Q38530583-075D28DF-ADEB-4197-9919-C1465F971DA2

Q38530583-0A61FD44-B980-4F2B-A57D-77346E71E619

Q38530583-1A648664-0E7B-4689-BD9E-DB02F134B310

Q38530583-20782062-250E-4AEA-9FE5-FC10F495A06E

Q38530583-20DECA76-7F09-4FDE-B3AB-B44E90E5729B

Q38530583-227B14FA-592D-4413-8F1A-CEBBD0E7E10F

Q38530583-268C1ACF-C7FF-457D-8EA9-23CDE75C4990

Q38530583-2C0A15A0-D2C5-4030-964C-33AF4F796A73

Q38530583-2D20CC0B-70EB-45DB-B6F4-63FC14DEA86A

Q38530583-2F2C4948-F4F5-4BE6-B12D-E8BF5291441C

P304

Q38530583-3587C309-60C7-44CF-BD69-041720CB1278

P31

Q38530583-DCA64BCA-914B-4476-9222-36E6C0A24EB1

P356

Q38530583-B7DD81F2-8CFC-410B-A3D8-2C82CEC66246

P433

Q38530583-DF1BED20-0A86-4D1C-9161-76E784D97BBD

P478

Q38530583-E6B89520-79E0-4245-8BFB-155791014A5F

P50

Q38530583-54EE4189-09D5-4F39-8EAF-E764E139C9E5

P577

Q38530583-3632C7E8-C796-45F9-B3A2-CD8138DAF805

P5875

Q38530583-76258B4B-F6AF-421C-BFA7-413DAEF2D145

P698

Q38530583-CF0ED45D-A9B2-4DCA-8045-BD39BAD05AD4

P356

P1433

European Journal of Haematology

P1476

Bendamustine in multiple myeloma.

@en

P2093

Ernesto Vigna

http://www.w3.org/2001/XMLSchema#string

Fortunato Morabito

http://www.w3.org/2001/XMLSchema#string

Francesco Mendicino

http://www.w3.org/2001/XMLSchema#string

Giovanna Giagnuolo

http://www.w3.org/2001/XMLSchema#string

Lucio Morabito

http://www.w3.org/2001/XMLSchema#string

Massimo Gentile

http://www.w3.org/2001/XMLSchema#string

P2860

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

P304

377-388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12609

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Anna Grazia Recchia

P577

2015-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278791602

http://www.w3.org/2001/XMLSchema#string

P698

26085055

http://www.w3.org/2001/XMLSchema#string